Explore Business Standard
Associate Sponsors
Co-sponsor
The deal will enable the company to continue marketing its generic Mirabegron in the United States, Zydus said, adding that other terms and conditions of the agreement are confidential
 "Zydus agrees to pay $120 million to settle US patent dispute with Astellas")
India's Zydus Lifesciences and its US unit will pay $120 million to Astellas Pharma as part of a deal to settle a patent dispute over the Japanese drugmaker's bladder disorder drug Mirabegron, the Indian firm said on Thursday.
Zydus and its unit will also pay a pre-paid per-unit licensing fee on sales of its generic Mirabegron in the US from the date of the agreement until September 2027, the company said.
The deal will enable the company to continue marketing its generic Mirabegron in the United States, Zydus said, adding that other terms and conditions of the agreement are confidential.
The announcement comes days after local peer Lupin decided to settle its dispute with Astellas over the same drug for $90 million.
At the time, analysts at brokerage Citi said the development could delay the entry of other generic rivals in the US market, potentially providing Zydus and Lupin with a period of limited competition.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
First Published: Feb 12 2026 | 9:57 AM IST
